Placebo + Mesalamine + Mesalamine
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Mild to Moderate Ulcerative Colitis
Conditions
Mild to Moderate Ulcerative Colitis
Trial Timeline
Jan 1, 2008 → Aug 1, 2009
NCT ID
NCT01045018About Placebo + Mesalamine + Mesalamine
Placebo + Mesalamine + Mesalamine is a phase 3 stage product being developed by Eagle Pharmaceuticals for Mild to Moderate Ulcerative Colitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01045018. Target conditions include Mild to Moderate Ulcerative Colitis.
What happened to similar drugs?
8 of 16 similar drugs in Mild to Moderate Ulcerative Colitis were approved
Approved (8) Terminated (2) Active (7)
Hype Score Breakdown
Clinical
17
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01045018 | Phase 3 | Completed |
Competing Products
20 competing products in Mild to Moderate Ulcerative Colitis